177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide.
about
Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumoursHigh clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours.Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT).Tumour targeting of Auger emitters using DNA ligands conjugated to octreotate.Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.The Challenges of Treating Paraganglioma Patients with (177)Lu-DOTATATE PRRT: Catecholamine Crises, Tumor Lysis Syndrome and the Need for Modification of Treatment ProtocolsLong-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide.Beta emitters rhenium-188 and lutetium-177 are equally effective in radioimmunotherapy of HPV-positive experimental cervical cancer.Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside.Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments.Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?Radionuclides in oncology clinical practice - review of the literature.Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion.The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors.Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study.Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy.The difference between medicine and magic is that magicians know what they are doingENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues
P2860
Q28247667-8032BD23-2EA8-4136-B3C6-04235E2341BEQ33435622-51F02414-6150-42B8-BF4B-D8ACE072D996Q34157391-0FAA4435-2664-45E1-BA8E-D46822C67930Q34174906-3B07B450-068B-46CF-B2F9-C011F8A289CBQ34256413-897F2603-99A0-4A07-922F-C4666E7D8BFBQ35941125-25409D7F-54B2-424A-89F2-CE608E845C69Q35999552-5511AA16-41A9-4F67-941B-95F0B5484A34Q36451556-69273C0B-9056-4F64-AA10-2C3ADFB16F85Q38965866-C8550FF6-330E-4C93-B266-EDF58F2A5B58Q42345704-4645B0B4-6831-4A01-AF76-1ACD50990D03Q44670305-BC563DF4-89A4-4811-8E9C-E93FBE5BFB63Q47916271-97E5C603-001F-4455-8D71-FE4F19C6D37EQ47988504-DA80D61C-1B50-4A42-B979-E8D6949EA5F7Q48295398-F269F5E7-C24C-48C9-BF4C-69A94D721678Q48342806-8679B2F6-D53A-47F6-B76F-C1091CEC09DEQ50143284-9194C115-EEA4-42FC-B41B-449437491D31Q53201630-46CADADE-A3DB-4CD6-8B0A-A96B9A6F4428Q57758762-76A10D67-A1BC-434C-BD7B-B8F9C311247AQ57990732-0AB0D595-52B6-4239-80AB-F0A3BFD5F279
P2860
177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
177Lu-octreotate, alone or wit ...... igh-activity 111In-octreotide.
@ast
177Lu-octreotate, alone or wit ...... igh-activity 111In-octreotide.
@en
type
label
177Lu-octreotate, alone or wit ...... igh-activity 111In-octreotide.
@ast
177Lu-octreotate, alone or wit ...... igh-activity 111In-octreotide.
@en
prefLabel
177Lu-octreotate, alone or wit ...... igh-activity 111In-octreotide.
@ast
177Lu-octreotate, alone or wit ...... igh-activity 111In-octreotide.
@en
P2093
P1476
177Lu-octreotate, alone or wit ...... igh-activity 111In-octreotide.
@en
P2093
Daniel Hubble
Grace Kong
Michael Michael
Shakher Ramdave
Val Johnson
P2888
P304
P356
10.1007/S00259-010-1483-4
P577
2010-05-06T00:00:00Z